Clinical Trial Update: Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer [Phase 2]

View source ↗

Summary

A phase 2 clinical trial evaluating disitamab vedotin combined with penpulimab as neoadjuvant therapy for HER2-low breast cancer is underway, with status curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Penpulimab

Snippet

Sponsor: West China Hospital | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN